New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
10:00 EDTANIKAnika Therapeutics falls 12.1%
Anika Therapeutics is down 12.1%, or $5.56, to $40.34
News For ANIK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
16:43 EDTANIKAnika announces Hyalofast abstracts, says 'positive clinical outcomes'
Anika Therapeutics announced that seven abstracts related to Hyalofast are scheduled for presentation at the 12th Annual World Congress of the International Cartilage Repair Society, May 8-11. "The research demonstrates that Anika’s HA-based scaffold, Hyalofast, enables patients to naturally regenerate cartilage. The research being presented on Hyalofast highlights the positive clinical outcomes of patients being treated in multiple areas, including the knees and ankles,” said Anika CEO Charles Sherwood. “The data validates the distinct advantages Hyalofast has over other products as the only HA-based scaffold for regeneration, as well as the safety and effectiveness of the procedure. We look forward to beginning a pivotal phase III clinical trial planned for Q4, and advancing Hyalofast toward commercialization in the United States," Sherwood added.
16:40 EDTANIKAnika Therapeutics targeting 5% Monovisc market share by end of FY15
Subscribe for More Information
16:39 EDTANIKAnika Therapeutics reports Q1 EPS 23c, two estimates 21c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use